Movatterモバイル変換


[0]ホーム

URL:


SG11201805497QA - Mutated truncated von willebrand factor - Google Patents

Mutated truncated von willebrand factor

Info

Publication number
SG11201805497QA
SG11201805497QASG11201805497QASG11201805497QASG11201805497QASG 11201805497Q ASG11201805497Q ASG 11201805497QASG 11201805497Q ASG11201805497Q ASG 11201805497QASG 11201805497Q ASG11201805497Q ASG 11201805497QASG 11201805497Q ASG11201805497Q ASG 11201805497QA
Authority
SG
Singapore
Prior art keywords
parkville
victoria
international
road
csl limited
Prior art date
Application number
SG11201805497QA
Inventor
Arna Andrews
Con Panousis
Kerstin Emmrich
Michael Wilson
Steve Dower
Matthew Hardy
Dallas Hartman
Original Assignee
Csl Behring Recombinant Facility Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900034Aexternal-prioritypatent/AU2016900034A0/en
Application filed by Csl Behring Recombinant Facility AgfiledCriticalCsl Behring Recombinant Facility Ag
Publication of SG11201805497QApublicationCriticalpatent/SG11201805497QA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101110101111110111011011111101111011111 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/117631 Al 13 July 2017 (13.07.2017) WI P0 I P CT (51) International Patent Classification: (74) Agent: DAVIS COLLISON CAVE; 1 Nicholson Street, A61K 38/36 (2006.01) C07K 14/745 (2006.01) Melbourne, Victoria 3000 (AU). A61K 38/37 (2006.01) A61P 7/04 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/AU2017/050010 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 6 January 2017 (06.01.2017) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (25) Filing Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (26) Publication Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (30) Priority Data: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 2016900034 7 January 2016 (07.01.2016) AU TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: CSL LIMITED [AU/AU]; 45 Poplar Road, Parkville, Victoria 3052 (AU). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, — (72) Inventors: ANDREWS, Arna; C/- CSL Limited, 45 Pop- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, lar Road, Parkville, Victoria 3052 (AU). PANOUSIS, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Kosta; C/- CSL Limited, 45 Poplar Road, Parkville, Vic- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, toria 3052 (AU). EMMRICH, Kerstin; C/- CSL Limited, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 45 Poplar Road, Parkville, Victoria 3052 (AU). WILSON, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, — _ Michael; C/- CSL Limited, 45 Poplar Road, Parkville, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Victoria 3052 (AU). DOWER, Steve; C/- CSL Limited, 45 GW, KM, ML, MR, NE, SN, TD, TG). Poplar Road, Parkville, Victoria 3052 (AU). HARDY, Mathew; C/- CSL Limited, 45 Poplar Road, Parkville, Published: . Victoria 3052 (AU). HARTMAN, Dallas; C/- CSL Lim- — with international search report (Art. 21(3)) ited, 45 Poplar Road, Parkville, Victoria 3052 (AU). — with sequence listing part of description (Rule 5.2(a)) = = = = = = = = = = 1-1 11 M IN 1-1 1-1 IN 1-1 (54) Title: MUTATED TRUNCATED VON WILLEBRAND FACTOR 0 N (57) : The present invention provides a modified polypeptide which binds Factor VIII. The polypeptide comprises trun- cated von Willebrand Factor (VWF) which comprises a sequence as shown in SEQ ID NO:3 or a fragment thereof or a sequence 90% identical thereto, wherein the truncated VWF comprises at least one modification in comparison to SEQ ID NO: 3 in at least one position selected from the group consisting of SI, S3, LI 8, V42, S43, K149, N248, S279, V320, T325, Q395 and K418.
SG11201805497QA2016-01-072017-01-06Mutated truncated von willebrand factorSG11201805497QA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
AU2016900034AAU2016900034A0 (en)2016-01-07Mutated truncated von willebrand factor
PCT/AU2017/050010WO2017117631A1 (en)2016-01-072017-01-06Mutated truncated von willebrand factor

Publications (1)

Publication NumberPublication Date
SG11201805497QAtrue SG11201805497QA (en)2018-07-30

Family

ID=59273076

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG10201912498YASG10201912498YA (en)2016-01-072017-01-06Mutated truncated von willebrand factor
SG11201805497QASG11201805497QA (en)2016-01-072017-01-06Mutated truncated von willebrand factor

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
SG10201912498YASG10201912498YA (en)2016-01-072017-01-06Mutated truncated von willebrand factor

Country Status (14)

CountryLink
US (1)US10806774B2 (en)
EP (1)EP3400002B1 (en)
JP (1)JP6851381B6 (en)
KR (1)KR20180094114A (en)
CN (1)CN108472338B (en)
AU (1)AU2017204955B2 (en)
BR (1)BR112018013861A2 (en)
CA (1)CA3010720A1 (en)
DK (1)DK3400002T3 (en)
ES (1)ES2909573T3 (en)
MX (1)MX2018008337A (en)
RU (1)RU2018128582A (en)
SG (2)SG10201912498YA (en)
WO (1)WO2017117631A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
SG11201805494WA (en)2016-01-072018-07-30Csl Behring Recombinant Facility AgMutated von willebrand factor
WO2018087267A1 (en)*2016-11-112018-05-17Csl Behring Recombinant Facility AgTruncated von willebrand factor polypeptides for treating hemophilia
CN110520150A (en)2016-12-022019-11-29比奥维拉迪维治疗股份有限公司Use the method for chimeric coagulation factor therapies hemophilic arthosis
PL3641800T3 (en)*2017-06-222024-03-18CSL Behring Lengnau AGModulation of fviii immunogenicity by truncated vwf
CN113039200B (en)*2018-05-182023-07-25郑州晟斯生物科技有限公司Improved FVIII fusion proteins and uses thereof
AU2019270184B2 (en)2018-05-182025-05-22Bioverativ Therapeutics Inc.Methods of treating hemophilia A
US10654911B1 (en)2019-04-022020-05-19Beijing Neoletix Biological Technology Co., Ltd.Vector co-expressing truncated von Willebrand factor and factor VIII
CN114072420B (en)*2019-07-042024-06-11康诺贝林伦瑙有限公司Truncated Von Willebrand Factor (VWF) for increasing the in vitro stability of coagulation factor VIII
CN110624105B (en)*2019-09-242021-06-11苏州大学Sequences of structurally sensitive polypeptide antigens of von Willebrand factor
US20220348637A1 (en)*2019-11-112022-11-03CSL Behring Lengnau AGPolypeptides for inducing tolerance to factor viii

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4399216A (en)1980-02-251983-08-16The Trustees Of Columbia UniversityProcesses for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU2353384A (en)1983-01-191984-07-26Genentech Inc.Amplification in eukaryotic host cells
US4713339A (en)1983-01-191987-12-15Genentech, Inc.Polycistronic expression vector construction
US4970300A (en)1985-02-011990-11-13New York UniversityModified factor VIII
FR2673632A1 (en)1991-03-081992-09-11Lille Transfusion Sanguine PROCESS FOR THE PREPARATION OF HUMAN VON WILLEBRAND FACTOR CONCENTRATE OF HIGH PURITY, SUITABLE FOR THERAPEUTIC USE
AU6029594A (en)1993-01-151994-08-15Enzon, Inc.Factor viii - polymeric conjugates
DE4435485C1 (en)1994-10-041996-03-21Immuno Ag Process for obtaining high-purity von Willebrand factor
JPH11501506A (en)1994-12-121999-02-09ベス イスラエル デアコネス メディカル センター Chimeric cytokines and their use
WO1997003193A1 (en)1995-07-111997-01-30Chiron CorporationNovel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (en)1995-09-291995-09-29Pharmacia Ab Protein derivatives
AU3202797A (en)1996-04-241997-11-12Regents Of The University Of Michigan, TheInactivation resistant factor viii
US20040092442A1 (en)1996-04-242004-05-13University Of MichiganInactivation resistant factor VIII
US6593294B1 (en)1998-04-272003-07-15Opperbas Holding B.V.Pharmaceutical composition comprising Factor VIII and neutral liposomes
US6660843B1 (en)1998-10-232003-12-09Amgen Inc.Modified peptides as therapeutic agents
US6887470B1 (en)1999-09-102005-05-03Conjuchem, Inc.Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP1351986A2 (en)2001-01-122003-10-15The American National Red CrossMethods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
JP4361786B2 (en)2001-06-142009-11-11ザ スクリプス リサーチ インスティチュート Stabilized proteins with engineered disulfide bonds
WO2003076567A2 (en)2002-03-052003-09-18Eli Lilly And CompanyHeterologous g-csf fusion proteins
US8586538B2 (en)2002-04-292013-11-19Stichting Sanquin BloedvoorzieningMethod of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII
WO2004058800A2 (en)2002-12-232004-07-15Bristol-Myers Squibb CompanyMammalian cell culture processes for protein production
US7041635B2 (en)2003-01-282006-05-09In2Gen Co., Ltd.Factor VIII polypeptide
HUE058897T2 (en)2003-02-262022-09-28Nektar TherapeuticsPolymer-factor viii moiety conjugates
TWI353991B (en)2003-05-062011-12-11Syntonix Pharmaceuticals IncImmunoglobulin chimeric monomer-dimer hybrids
DK2298347T3 (en)2003-05-062016-01-11Biogen Hemophilia Inc COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
WO2005000892A2 (en)2003-06-122005-01-06Eli Lilly And CompanyGlp-1 analog fusion plroteins
BRPI0417916A (en)2003-12-312007-04-10Merck Patent Gmbh fc-erythropoietin fusion protein with improved pharmacokinetics
US7670595B2 (en)2004-06-282010-03-02Merck Patent GmbhFc-interferon-beta fusion proteins
BR122016022033B8 (en)2004-11-122021-05-25Bayer Healthcare Llc isolated polypeptide conjugates showing factor viii procoagulant activity, their use and pharmaceutical composition
DK1835938T3 (en)2004-12-272013-11-04Baxter Int Polymer-von Willebrand factor conjugates
AU2006233638A1 (en)2005-04-142006-10-19Csl Behring GmbhModified coagulation Factor VIII with enhanced stability and its derivates
EP1816201A1 (en)2006-02-062007-08-08CSL Behring GmbHModified coagulation factor VIIa with extended half-life
NZ572050A (en)2006-03-312011-09-30Baxter IntFactor VIII conjugated to polyethylene glycol
DK3896090T3 (en)2006-06-142022-03-21Csl Behring Gmbh PROTEOLYTIC SPLIT FUSION PROTEIN INCLUDING A BLOOD COAGAGATION FACTOR
JP5448839B2 (en)2006-12-222014-03-19ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Modified clotting factor with long half-life in vivo
CA2704234A1 (en)*2007-11-092009-05-14Baxter International Inc.Modified recombinant factor viii and von willebrand factor and methods of use
DK2865760T3 (en)2008-06-242018-01-15Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
KR101874834B1 (en)2009-10-302018-07-05알부메딕스 에이/에스Albumin variants
US8759293B2 (en)2009-11-132014-06-24Grifols Therapeutics Inc.von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
KR20130070576A (en)2010-04-092013-06-27노보자임스 바이오파마 디케이 에이/에스Albumin derivatives and variants
EP2635598A1 (en)2010-11-012013-09-11Novozymes Biopharma DK A/SAlbumin variants
CN104011072B (en)2011-05-052018-10-12阿尔布梅迪克斯医疗有限公司albumin variants
WO2013093760A2 (en)*2011-12-192013-06-27Grifols, S.A.Compositions, methods, and kits for preparing sialylated recombinant proteins
PL2804623T3 (en)2012-01-122020-03-31Bioverativ Therapeutics Inc.Chimeric factor viii polypeptides and uses thereof
WO2013120939A1 (en)2012-02-152013-08-22Csl Behring GmbhVon willebrand factor variants having improved factor viii binding affinity
PL2825556T3 (en)2012-03-162018-10-31Albumedix A/SAlbumin variants
EP2841451A1 (en)2012-04-242015-03-04Novo Nordisk A/SCompounds suitable for treatment of haemophilia
HUE047088T2 (en)2012-07-112020-04-28Bioverativ Therapeutics IncFactor viii complex with xten and von willebrand factor protein, and uses thereof
JP6487328B2 (en)2012-11-082019-03-20アルブミディクス リミティド Albumin variant
CN105452289A (en)2013-06-122016-03-30诺和诺德股份有限公司Compounds suitable for treatment of haemophilia
ES2895798T3 (en)*2014-06-062022-02-22Octapharma Ag Preparation comprising peptides of factor VIII and von Willebrand factor
BR112016030950A2 (en)2014-07-022018-03-27Csl Ltd modified factor viii binding polypeptide, complex, pharmaceutical composition, methods for treating a coagulopathy, to produce a polypeptide comprising a modified vwf, and to increase vwf factor viii binding affinity and factor viii half-life, use of a modified polypeptide or complex, polynucleotide, plasmid or vector, and host cell.
US10364982B2 (en)*2015-11-192019-07-30Ansaldo Energia Switzerland AGMethod for reconditioning fuel nozzle assemblies
SG11201805494WA (en)2016-01-072018-07-30Csl Behring Recombinant Facility AgMutated von willebrand factor

Also Published As

Publication numberPublication date
JP6851381B6 (en)2021-04-21
MX2018008337A (en)2018-09-17
JP6851381B2 (en)2021-03-31
EP3400002A4 (en)2019-07-03
AU2017204955A1 (en)2018-07-12
US10806774B2 (en)2020-10-20
HK1256525A1 (en)2019-09-27
EP3400002A1 (en)2018-11-14
DK3400002T3 (en)2022-04-11
KR20180094114A (en)2018-08-22
ES2909573T3 (en)2022-05-09
BR112018013861A2 (en)2018-12-18
US20190015483A1 (en)2019-01-17
CN108472338A (en)2018-08-31
EP3400002B1 (en)2022-02-02
CN108472338B (en)2022-12-30
SG10201912498YA (en)2020-02-27
JP2019507587A (en)2019-03-22
AU2017204955B2 (en)2021-04-01
RU2018128582A (en)2020-02-11
CA3010720A1 (en)2017-07-13
WO2017117631A1 (en)2017-07-13

Similar Documents

PublicationPublication DateTitle
SG11201805497QA (en)Mutated truncated von willebrand factor
SG11201805494WA (en)Mutated von willebrand factor
SG11201810933QA (en)Anti-c5 antibodies and uses thereof
SG11201808622SA (en)Chimeric receptors to flt3 and methods of use thereof
SG11201805709RA (en)Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201407486PA (en)Compositions and methods for modulating utrn expression
SG11201903857UA (en)Antibodies to pd-1 and uses thereof
SG11201803848YA (en)Fluxed deasphalter rock fuel oil blend component oils
SG11201901700UA (en)Biaryl compounds useful as immunomodulators
SG11201907855QA (en)Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201809344QA (en)Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201809912UA (en)Hybrid carriers for nucleic acid cargo
SG11201807301SA (en)Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201907889YA (en)Glycan-interacting compounds and methods of use
SG11201907209QA (en)Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
SG11201806398YA (en)Optimized factor viii genes
SG11201810420YA (en)Antibodies to alpha-synuclein and uses thereof
SG11201804674UA (en)Heteroarylhydroxypyrimidinones as agonists of the apj receptor
SG11201806544XA (en)Compounds and methods of treating rna-mediated diseases
SG11202000333UA (en)Bicyclic ketone compounds and methods of use thereof
SG11201908056QA (en)Anti-par2 antibodies and uses thereof
SG11201804589TA (en)Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11201809764XA (en)Humanized anti-il-1r3 antibodies
SG11201810853UA (en)Anti-tnfrsf25 antibodies
SG11201804704PA (en)Compositions and methods for decreasing tau expression

[8]ページ先頭

©2009-2025 Movatter.jp